[SCHEDULE 13G/A] Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock SEC Filing

Rhea-AI Filing Summary

Yap Kim Choy filed an amendment on Schedule 13G reporting beneficial ownership in Cyclacel Pharmaceuticals, Inc. common stock totaling 872,000 shares or equivalents, representing 20.76% of the class. The filing states the position consists of 218,000 common shares and 218,000 warrants in each of three series (A, B and C) that together account for the aggregate amount. The filer reports sole voting and dispositive power over the full amount and certifies the securities were not acquired to change or influence control of the issuer. The filing includes links to the amended and restated warrant forms as exhibits.

Insights

Securities Analyst

TL;DR: A single holder reports a meaningful 20.76% economic interest composed of shares plus warrants, with sole voting and dispositive power.

The disclosure shows a concentrated position equal to just over one-fifth of the outstanding class, combining current common shares and multiple series of warrants convertible into common stock. Sole voting and dispositive power indicates the filer controls voting and disposition decisions for the reported position. The certification that the stake was not acquired to influence control is standard for this filing type, but investors should note the aggregated ownership includes exercisable instruments that can affect future share count and voting dynamics if exercised.

Corporate Governance Expert

TL;DR: Beneficial owner reports sole control of a material 20.76% stake comprised of shares and warrants; filing asserts no intent to change control.

The Schedule 13G/A reports sole voting and dispositive authority over 872,000 shares or equivalents, which is a material block for corporate governance considerations. The inclusion of series A, B and C warrants in the ownership calculation is important because warrant exercise could increase the filer’s economic and voting exposure. The filer’s signature includes the required certification asserting non-control purpose, aligning this filing with passive investor disclosure rules rather than a Schedule 13D activist disclosure.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Cyclacel Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

23254L876

(CUSIP Number)

09/01/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 23254L876

1

Names of Reporting Persons

Yap Kim Choy

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MALAYSIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 872,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 872,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

872,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

20.76 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: The reporting person's ownership consists of (i) 218,000 shares of common stock, (ii) 218,000 series A warrants to purchase shares of common stock, (iii) 218,000 series B warrants to purchase shares of common stock, and (iv) 218,000 series C warrants to purchase shares of common stock (the series A warrants, series B warrants and series C warrants, collectively, the "Warrants")

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Cyclacel Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: Level 10, Tower 11, Avenue 5, No. 8 Jalan Kerinchi, Kuala Lumpur, Malaysia
Item 2.
(a)	Name of person filing: Yap Kim Choy
(b)	Address or principal business office or, if none, residence: 18-25-3A THE WHARF RESIDENCE TAMAN PUCHONG PRIMA PUCHONG 47200 SELANGOR MALAYSIA
(c)	Citizenship: Malaysia
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 23254L876
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 872,000
(b)	Percent of class: 20.76%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 872,000
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 872,000
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Yap Kim Choy

Signature:	/s/ Yap Kim Choy
Name/Title:	Yap Kim Choy
Date:	09/01/2025

Exhibit Information

Form of Amended and Restated Series A Common Stock Warrant Form of Amended and Restated Series B Common Stock Warrant Form of Amended and Restated Series C Common Stock Warrant sec.gov/Archives/edgar/data/1130166/000164117225015874/ex10-1.htm sec.gov/Archives/edgar/data/1130166/000164117225015874/ex10-2.htm sec.gov/Archives/edgar/data/1130166/000164117225015874/ex10-3.htm sec.gov/Archives/edgar/data/1130166/000164117225015874/ex10-4.htm